NEWSROOM

New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health

January 3, 2019

IQcast Feature Aims to Predict the Likelihood of a Low Glucose Event Up to Four Hours in Advance

DUBLIN and CAMBRIDGE, Mass. - January 3, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, and its strategic technology partner, IBM (NYSE:IBM) Watson Health, today announced a new feature for the Sugar.IQ(TM) personal diabetes assistant app called IQcast(TM). Using artificial intelligence (AI) technology from IBM Watson Health, the feature aims to predict the likelihood of an individual experiencing a low glucose event within an upcoming 1-4 hour window.

Read more >

Medtronic to Acquire Nutrino Health

November 21, 2018

(GLOBE NEWSWIRE via COMTEX) --Acquisition to Augment Diabetes Capabilities with Nutritional Database and Data Science

DUBLIN and TEL AVIV, Israel - November 21, 2018 - Medtronic plc (NYSE:MDT), a global leader in medical technology, and Nutrino Health Ltd., a leading provider of nutrition-related data services, analytics, and technologies, today announced the companies have entered into a definitive agreement under which Medtronic will acquire Nutrino. Given that food and nutrition are central components in effective diabetes management, the companies recognized an opportunity to improve clinical outcomes for people with diabetes by integrating Nutrino's extensive food analysis infrastructure, nutrition science expertise and artificial intelligence (AI)-driven personalized insights with Medtronic's technology and future innovations.

Read more >

Medtronic Launches Patient Engagement Program That Leverages Gamification to Help Motivate and Engage Patients Living with Diabetes

August 9, 2018

(GLOBE NEWSWIRE via COMTEX) --DUBLIN - August 9, 2018 - Medtronic today announced the official U.S. launch of the Medtronic Inner CircleSM patient engagement program, which uses gamification - the application of game design elements - to motivate and encourage people living with diabetes to achieve better health outcomes.

Read more >

Medtronic Launches the MiniMed(TM) 670G System Performance Guarantee for Payers and Employers

June 28, 2018

(GLOBE NEWSWIRE via COMTEX) --DUBLIN- June 28, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the launch of the MiniMed(TM) 670G Performance Guarantee Program - an outcomes-based offering for payers and employers designed to mitigate costs for diabetes-related complications. With this Guarantee, Medtronic will provide flat-fee reimbursements up to $25,000 per pump over 4 years for qualifying diabetes-related inpatient hospitalization and emergency room admissions for eligible in-network patients in the United States.

Read more >

Medtronic Receives CE Mark for MiniMed(TM) 670G Hybrid Closed Loop System

June 25, 2018

(GLOBE NEWSWIRE via COMTEX) --DUBLIN - June 25, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the MiniMed(TM) 670G hybrid closed loop system - the first and only system to automate and personalize the delivery of basal insulin 24 hours a day1. The system is CE Mark approved for the treatment of people with type 1 diabetes 7 years of age and older with ongoing studies to expand the indication to additional patient populations.

Read more >

View all Announcements >





Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Janet Kim
Director, Communications
818-576-5014
janet.kim@medtronic.com

Pamela Reese
Director, Communications
818-576-3398
pamela.s.reese@medtronic.com

For all other media inquiries please select the appropriate Global Public and Media Relations contact

Media Kits